FZD10 (UniProt# Q9ULW2) is a member of the Frizzled family of proteins, which function as receptors in the Wnt signaling pathway. It plays a key role in mediating Wnt signaling, which is essential for processes such as cell proliferation, differentiation, and migration. FZD10 is primarily expressed during embryonic development and in specific adult tissues, but it is also notably overexpressed in certain cancers. 

FZD10 has been strongly associated with cancer, especially synovial sarcoma and colorectal cancer. Its overexpression in tumor cells makes it a promising target for cancer diagnosis and therapy. Researchers are exploring antibody-based therapies and radiolabeled treatments that specifically target FZD10-expressing cells. FZD10 is an important Wnt receptor involved in developmental signaling and disease, particularly cancer, making it a significant focus of biomedical research.

FZD10 antibodies can be used in various applications such as Western blot, immunohistochemistry, immunofluorescence, flow cytometry, and ELISA. Monoclonal antibodies for high specificity and reproducibility can advance in vitro assays. Conigen’s FZD10-specific live cell staining mouse mAb is a great selection as a research antibody for flow cytometry and other in vitro binding assays. A live cell binding antibody is critical for flow cytometry when studying cell surface FZD10 in its native state. It binds to extracellular epitopes on intact, viable cells without fixation or permeabilization, preserving physiological structure and function. It can be used for mechanism-of-action studies and drug discovery workflows, where FZD10 expression can be elevated.